Cargando…

Phase 1 Clinical Trial of a Replication-Defective Human Cytomegalovirus (CMV) Vaccine

BACKGROUND: Congenital CMV remains an unmet medical need worldwide. Naturally acquired CMV immunity in women prior to pregnancy has been shown effective in reducing maternal-fetal transmission. V160 is engineered as a replication-defective CMV, and its replication in culture is controlled by a synth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adler, Stuart, Lewis, Nicole, Conlon, Anthony, Christiansen, Mark, Al-Ibrahim, Mohamed S, Rupp, Richard, Fu, Tong Ming, Bautista, Oliver, Tang, Huaping, Culp, Timothy, Das, Rituparna, Beck, Karen, Tamms, Gretchen, Musey, Luwy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631465/ http://dx.doi.org/10.1093/ofid/ofx163.718

Ejemplares similares

1048. Double-Blind, Randomized, Placebo-Controlled Phase 2b Multicenter Trial of V160, a Replication-Defective Human Cytomegalovirus (CMV) Vaccine
por: Das, Rituparna, et al.
Publicado: (2021)

THE PREVALENCE OF CYTOMEGALOVIRUS (CMV) VIRURIA AMONG HOSPITALIZED CHILDREN AND THE RISK OF CMV ACQUISITION BY NURSES
por: Adler, Stuart P, et al.
Publicado: (1984)

P08 A Phase 1, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (PCV) (V116) in adults
por: Platt, Heather, et al.
Publicado: (2023)

Cytomegalovirus (CMV) Infection and Latency
por: O’Connor, Christine M.
Publicado: (2021)

Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen
Publicado: (1990)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies
por: Han, Sang Hoon
Publicado: (2017)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Cytomegalovirus (CMV) seroprevalence in the adult population of Germany
por: Lachmann, Raskit, et al.
Publicado: (2018)

Acute Cytomegalovirus (CMV) Hepatitis in an Immunocompetent Adult
por: Zahid, Maleeha, et al.
Publicado: (2020)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial
por: Li, Leike, et al.
Publicado: (2021)

1174. Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU–PLAN)
por: Banniettis, Natalie, et al.
Publicado: (2021)

Detection of cytomegalovirus (CMV) by digital PCR in stool samples for the non-invasive diagnosis of CMV gastroenteritis
por: Gu, Jia, et al.
Publicado: (2022)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation
por: Rea, Federico, et al.
Publicado: (2016)

Detection of Cytomegalovirus (CMV) in Saliva of Congenitally Infected Neonates
por: Wissel, Mark, et al.
Publicado: (2017)

Cytomegalovirus (CMV) Pneumonitis: Cell Tropism, Inflammation, and Immunity
por: Fonseca Brito, Luís, et al.
Publicado: (2019)

Antiviral Treatment of Maternal and Congenital Cytomegalovirus (CMV) Infections
por: Pinninti, Swetha, et al.
Publicado: (2023)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients
por: Lee, Hyeyoung, et al.
Publicado: (2017)

“Targeted” Screening for Cytomegalovirus (CMV)-Related Hearing Loss: It’s Time for Universal CMV Screening in the NICU!
por: Medoro, Alexandra, et al.
Publicado: (2017)

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies
por: Chapman, Timothy J., et al.
Publicado: (2023)

Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies
por: Burbelo, Peter D, et al.
Publicado: (2009)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

Human cytomegalovirus (CMV) in Africa: a neglected but important pathogen
por: Bates, Matthew, et al.
Publicado: (2016)

LB17. Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
por: Hughes, Brenna
Publicado: (2019)

Thrombosis Associated With Cytomegalovirus (CMV) in a Kidney Transplant Recipient
por: Wang, Lin, et al.
Publicado: (2021)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

998 Detection of Cytomegalovirus (CMV) in Cerebrospinal Fluid of Infants with Congenital CMV Infection: Is It Worth Doing the Lumbar Puncture?
por: Ouellette, Christopher, et al.
Publicado: (2014)

Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant
por: Kim, Taeeun, et al.
Publicado: (2020)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact
por: Valle-Arroyo, Jorge, et al.
Publicado: (2020)

1198. Measurement of Pre-transplant Anti-cytomegalovirus (CMV) Immunoglobulin G Titer to Predict Risk of CMV Infection in CMV-seropositive Kidney Transplant Recipients
por: Kirisri, Similan, et al.
Publicado: (2020)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Latent Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-Specific T Cells
por: Jackson, Sarah E., et al.
Publicado: (2017)

Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of anti-CMV IgG in Chinese children
por: Chen, Jie, et al.
Publicado: (2012)

Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease
por: Nowacki, Tobias M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7cjvjuu72tm86f7m67erh7hghd